Sepsis marker | Evaluated in experimental studies | Evaluated in clinical studies | Evaluated as a prognostic factor | Comment |
---|---|---|---|---|
CC chemokine receptor (CCR) 2 [95] | √ |  |  |  |
CCR 3 [96] |  | C | √ | Distinguished between survivors and non-survivors at 28 days |
C5L2 [97] | √ | B | √ | Predicted development of MOF |
CRTh2 [98] |  | C | √ | Distinguished between survivors and non-survivors at 28 days |
Fas receptor (soluble) [99] |  | B(m) | √ | Predicted development of MOF |
Fc-gamma RIII [100] |  | A | √ | Increased in sepsis compared with healthy controls, correlated with APACHE II score |
√ | C | √ | Correlated with APACHE II score | |
GP130 [103] | Â | A | Â | Increased in sepsis compared with healthy controls |
IL-2 receptor (soluble) [104] |  | C | √ | Predicted development of septic shock |
√ | B |  | Distinguished between survivors and non-survivors at 28 days | |
RAGE (soluble) [107] |  | B | √* | Distinguished between survivors and non-survivors at 28 days |
ST2 (soluble, IL-1 receptor) [108] |  | A(s) | √ | Increased in sepsis compared with healthy controls |
Toll-like receptor (TLR) 2 and 4 [109] | √ | B | √ | Increased in septic compared with non-septic critically ill patients |
Transient receptor potential vanilloid (TRPV)1 [110] | √ |  |  |  |
√ | C | √ | Distinguished between survivors and non-survivors at 28 days | |
TNF-receptor (soluble) [113] | Â | B | Â | Predicted development of MOF |
Urokinase type plasminogen activator receptor (uPAR) (soluble) [114] |  | C(m) | √ | Distinguished between survivors and non-survivors at 28 days |